Ụlọ ọrụ China Biotech [Pharma] 10 kacha elu

Emelitere ikpeazụ na Septemba 7, 2022 na 01:28 ehihie

N'ebe a, ị nwere ike ịchọta ndepụta nke Top 10 Chinese Biotech [Pharma] ụlọ ọrụ na Financials , Revenue na Profaịlụ nke ụlọ ọrụ ọ bụla

Ndepụta ụlọ ọrụ China Biotech [Pharma] kacha elu 10

Ya mere, ebe a bụ Ndepụta nke

1. Guangzhou Baiyunshan Pharmaceutical Group

Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd bụ ụlọ ọrụ edepụtara nke Guangzhou Pharmaceutical Group Co., Ltd. (A mbak 600332, H shares 00874), na-etinye aka na:

1. Chinese na Western patent ọgwụ, chemical akụrụngwa, eke ọgwụ, ndu ọgwụ, chemical akụrụngwa R&D, n'ichepụta na ire nke intermediates;
2. N'ogbe, retail na mbubata na mbupụ ọgwụ ọdịda anyanwụ, ọgwụ ọdịnala China na akụrụngwa ọgwụ;
3. R & D, mmepụta na ire ahịa nke isi ngwaahịa ahụike; na
4. Ọrụ ahụike na njikwa ahụike, nlekọta ahụike na ụgwọ ezumike nka na ntinye ego ụlọ ọrụ ahụike ndị ọzọ, wdg. 

Otu a nwere ngụkọta nke ọgwụ iri abụọ na ise ụlọ ọrụ na-emepụta ihe na ụlọ ọrụ (gụnyere alaka 3, ndị enyemaka 19 na-ejide ya na njikọ 3), gụnyere 12 ndị China na-asọpụrụ oge. -emepụta ọgwụ na ụlọ ọrụ ndị na ụlọ ọrụ 10 narị afọ; Ngwaahịa ọgwụ ndị China pụrụiche Enwere ihe karịrị 100 ụkpụrụ (gụnyere ndị enyemaka na njikọ aka).

• Ego ha nwetara: CNY ijeri 79

Mgbe ọtụtụ afọ nke nlezianya wuo na mmepe ngwa ngwa, otu ahụ ejirila nwayọọ nwayọọ guzobe ngalaba azụmahịa anọ: "Great Southern Medicine", "Big Health", "Big Business" na "Big Medical", yana "E-azụmahịa", " Ego ego" na "ngwaọrụ ahụike". “Ụdị ọhụrụ atọ. 

2. China National Accord Medicines Corporation

China National Accord Medicines Corporation Ltd bụ ụlọ ọrụ sitere na China na-etinyekarị aka na azụmaahịa azụmaahịa, azụmaahịa na nrụpụta ọgwụ.

Isi ngwaahịa nke ụlọ ọrụ ahụ gụnyere nkwadebe ọgwụ nje, ike injections, ọgwụ nje Active Pharmaceutical Ingredients (API), ọgwụ usoro iku ume na ọgwụ obi na akwara ọbara, n'etiti ndị ọzọ.

• Ego ha nwetara: CNY ijeri 67

Ụlọ ọrụ ahụ na-etinyekwa aka n'ịkwado ngwa ngwa na ọrụ nchekwa, ọrụ mgbazinye na ọrụ ọzụzụ, n'etiti ndị ọzọ. Ụlọ ọrụ na-ekesa ngwaahịa ya tumadi n'ahịa ụlọ.

3. China National Pharmaceutical

China National Pharmaceutical and Healthcare Industry Co., Ltd bụ ụlọ ọrụ edepụtara ahaziri nke steeti depụtara na Shanghai Stock Exchange (mbiri ngwaahịa: China National Pharmaceutical; koodu ngwaahịa: 600056).

Onye na-achịkọta òkè bụ China General Technology (Group) Holdings Co., Ltd. N'isi obodo edebanyere aha nke ijeri yuan 1.068, ụlọ ọrụ ahụ bụ otu n'ime ụlọ ọrụ etiti atọ nwere ụlọ ọrụ ọgwụ dị ka isi azụmahịa ya.

• Ego ha nwetara: CNY ijeri 56

Onye bu ụzọ nke China National Pharmaceutical bụ ụlọ ọrụ China National Medicines and Health Products Import and Export Corporation n'okpuru Ministry of Foreign Trade and Economic Cooperation na 1984.

Ọ bụ ya na-ahụ maka ụlọ ọrụ ọgwụ na ngwaahịa ahụike mbata na mbubata na mbupụ. Ọ sonyeere China General Technology Group na 1999 wee bụrụ naanị onye enyemaka nke otu ahụ ka emezigharịrị ọgwụ. akụ n'ime otu.

4. Nanjing Pharmaceutical Factory

Nanjing Pharmaceutical Factory Co. Ltd bụ na mbụ chọtara na 1935 ma bụrụ otu n'ime ndị na-emepụta ihe na National Pharmaceutical Industry. Mgbe nhazigharị ihe onwunwe nke Shenzhen Anyuan Investment Group gasịrị na 2000, Nanjing Pharmaceutical Factory na-aghọ nnukwu ụlọ ọrụ ọgwụ na-ejikọta R & D, mmepụta na ahịa nke API (Active Pharmaceutical Ingredients), formulations na intermediates.

The ọhụrụ management adjusts ngwaahịa akara na ụlọ ọrụ si mmepe atụmatụ, Na-erube site na "na-elekọta ndụ, na-etinye aka na ahụike" nkà ihe ọmụma, Nanjing Pharmaceutical Factoty ga unswervingly ime ka ukwuu na-eme ka mma ndụ mmadụ na ahụike n'okpuru nduzi nke "mgbanwe na ọhụrụ".

• Ego ha nwetara: CNY ijeri 39

Ebe nrụpụta API, nke dị na Nanjing Chemical Industrial Park, nwere osisi mmepụta isii gụnyere ụlọ ọrụ pụrụ iche na ọtụtụ ebumnuche. Ntọala ahụ agafeela nyocha GMP nke mba na nke mba ụwa ọtụtụ oge. A na-ere ihe fọrọ nke nta ka ọ bụrụ ụdị API iri abụọ n'ahịa ụlọ na nke esenidụt.

Isi ihe nrụpụta ahụ dị na Nanjing Xingang Economic & Teknụzụ Development Mpaghara, yana ogbako injection (uzuzu sitere na antineoplastic na mmiri injections) na ogbako nkwadebe ọnụ siri ike (mbadamba, capsules na granules). Ntọala ahụ agafeela nyocha GMP nke mba ọtụtụ oge. A na-ere ihe karịrị ụdị nkwadebe iri abụọ na China niile.

5. Yunnan Baiyao

Emepụtara Yunnan Baiyao na 1902, akara azụmaahịa ama ama na China, yana sokwa n'òtù mbụ nke ụlọ ọrụ mmepụta ihe nke mba. Ọ bụ akara China a ma ama na-asọpụrụ oge ma n'ụlọ na mba ọzọ.

Na 1971, factory e guzobere dị ka ntuziaka nke Premier Zhou Enlai. Na 1993, edepụtara ya na Shenzhen Stock Exchange dị ka ụlọ ọrụ mbụ edepụtara na Yunnan.

• Ego ha nwetara: CNY ijeri 32
• Guzosie ike: 1902

E kewara ụlọ ọrụ ahụ ụzọ anọ bụ isi: ọgwụ, ngwaahịa ahụike, akụrụngwa ọgwụ ọdịnala ndị China, na ngwa ọgwụ.

Ngalaba ọ bụla nwere onwe ya ma na-akwado ibe ya, na-etolite site na ozuzu, akuku, nyocha na mmepe, n'ichepụta na usoro uru ahịa nke usoro ụlọ ọrụ niile nke ngwaahịa na ọrụ ahụike na-etolite usoro akụ na ụba na njikọta nke ụlọ ọrụ tertiary na uru bara uru. mmepe nke otutu ngalaba.

6. Shandong Realcan Pharmaceutical Group

Shandong Realcan Pharmaceutical Group bụ ụlọ ọrụ na-ere ọgwụ, ngwaọrụ ahụike na ihe oriri ahụike nye ụlọ ọrụ ahụike n'ofe mba ahụ. O nwekwara ngalaba ọrụ asatọ dị mkpa gụnyere teknụzụ ego, ọgwụ ọdịnala ndị China, ọgwụ dijitalụ, agụmakwụkwọ ọgwụ, ngwa ngwa ọkachamara, ngwaọrụ R&D na mmepụta, nyocha ahụike, yana njikọta ngwaọrụ. Onye na-ahụ maka ahụike.

Shandong Realcan Pharmaceutical Group e hiwere na Septemba 21, 2004 na isi obodo edebanye aha nke yuan ijeri 1.5. O nwere ihe karịrị ndị enyemaka 130 yana karịa 12,000 ọrụ. 

• Ego ha nwetara: CNY ijeri 28
• Guzosie ike: 2004
• Ndị ọrụ: 12000

The ụlọ ọrụ e depụtara na Shenzhen A-oke ahịa na June 2011 na ngwaahịa koodu 002589. Ya ahịa netwọk na-ekpuchi 31 ógbè na obodo n'ofe mba, ozugbo na-eje ozi karịa 42,000 ọgwụ ụlọ ọrụ, na azụmahịa ekpuchi fọrọ nke nta niile anụ ụlọ na mba ọzọ emepụta n'elu. ahaziri nha.

7. Jiangsu Hengrui Pharmaceutical

Jiangsu Hengrui Pharmaceutical Co., Ltd bụ ụlọ ọrụ na-emepụta ọgwụ na ahụike na-etinye aka na mmepụta ọgwụ na ọgwụ R&D dị elu, mmepụta na nkwalite.

E hiwere ya na 1970 wee depụta ya na Shanghai Stock Exchange na 2000. Dị ka njedebe nke 2019, o nwere ihe karịrị ndị ọrụ 24,000 n'ụwa niile. Ọ bụ onye ama ama n'ime ụlọ na-ebubata ọgwụ mgbochi tumor, ọgwụ ịwa ahụ na ndị nnọchi anya dị iche, ma bụrụkwa onye isi ngalaba nke National Anti-tumor Drug Technology Innovation Industry-University-Research Alliance.

• Ego ha nwetara: CNY ijeri 26

O guzobela ebe National Ezubere iche maka Drug Engineering Technology Research Center na ebe nyocha post-doctoral. N'afọ 2019, ụlọ ọrụ ahụ nwetara ego ọrụ nke ijeri yuan 23.29 na ụtụ isi nke ijeri yuan 2.43, wee họrọ ya na ndepụta TOP50 nke ụlọ ọrụ na-emepụta ọgwụ zuru ụwa ọnụ, ọkwa 47th.

N'ime afọ ndị na-adịbeghị anya, ụlọ ọrụ ahụ etinyela ihe dịka 15% nke ahịa ya na nyocha na ego mmepe. Na 2019, o tinyela ngụkọta nke ijeri yuan 3.9 na ego nyocha na mmepe, aza ajụjụ maka 16.7% nke ego ha nwetara. 

Ụlọ ọrụ ahụ eguzobewo ụlọ ọrụ R & D ma ọ bụ alaka na United States, Europe, Japan, na China, ma wuo otu R & D nke ihe karịrị mmadụ 3,400, gụnyere ihe karịrị 2,000 dọkịta, nna ukwu na ihe karịrị 200 lọta. N'ime afọ ndị na-adịbeghị anya, ụlọ ọrụ ahụ emeela 44 isi ọrụ pụrụ iche nke mba, ma nwee ọgwụ ọhụrụ 6, irecoxib, apatinib, thiopefilgrastim, pirotinib, carrelizumab na toluene Remazolam acid ka akwadoro maka ịzụ ahịa, otu ụdị ọgwụ ọhụrụ dị n'okpuru mmepe ụlọ ọgwụ, na a A na-emepụta ọnụọgụ ọgwụ ọhụrụ n'ụlọ ọgwụ na United States. 

Ụlọ ọrụ ahụ etinyela akwụkwọ maka ngụkọta nke patent 894 mepụtara ụlọ, nwere akwụkwọ ikike ime ụlọ 201 ziri ezi, yana 286 ikike ikike mba ọzọ dị ka Europe, America na Japan. Nkà na ụzụ bụ isi ya emeriela 2 ọkwa abụọ nke National Science and Technology Progress Awards na 1 China Patent Gold Award.

8. Renfu Pharmaceutical Group

Renfu Pharmaceutical Group Co., Ltd. e hiwere na 1993 wee depụta ya na Shanghai Stock Exchange na 1997 (600079.SH). Ụlọ ọrụ na-eduga ụlọ ọrụ ọgwụ na mpaghara Hubei, ụlọ ọrụ na-emepụta ọgwụ na China Top 100, Ụlọ ọrụ Ngosipụta Ngosipụta Sayensị na Nkà na Ụzụ Mba.

Ụlọ ọrụ ahụ na-agbaso atụmatụ nke "ịbụ onye ndu na ahịa ọgwụ ngalaba”, ma guzobe ọkwa na-eduga na ọgwụ anestetiiki ụlọ, analgesics, ndị na-achịkwa ọmụmụ, ọgwụ Uyghur na ngalaba ndị ọzọ; N'otu oge ahụ, ọ na-arụsi ọrụ ike na-emepe azụmahịa ahịa ọgwụ ma na-akwalite usoro mba ụwa. , Iji nweta R&D zuru ụwa ọnụ, ahịa na nhazi ụlọ ọrụ na United States na Africa.

Dị ka a "Nationally ghọtara Enterprise Technology Center" na "National Major New Drug Development Project Undertaking Unit", ụlọ ọrụ na-ekwusi ike na-ewere R&D dị ka onye na-ebu ụzọ, na bụ na mbụ nke anụ ụlọ ọgwụ ụlọ ọrụ 'R & D ego na ọhụrụ ọgwụ R&D ọganihu.

E hiwere ya na mmekorita ya na ulo akwukwo Chinese nke sayensi agha agha. Junke Optics Valley Innovative Drug R&D Center” duuru nguzobe nke "Hubei Biomedical Industry Technology Research Institute", raara onwe ya nye iwu ụlọ mbụ ọgwụ R&D ụlọ ọrụ mmepụta ihe.

9. Sichuan Kelun Pharmaceutical

Kelun bụ ụlọ ọrụ na-emepụta ọgwụ pụrụ iche na nke ọhụrụ na-enweta ego ọrịre kwa afọ karịa ijeri yuan 40. Ọ gụnyere Sichuan Kelun Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Klus Pharma Inc. (Kelun, USA), na KAZ Pharmaceutical Co., Ltd. (Kazakhstan Kelun), Sichuan Kelun Pharmaceutical Trading Co., Ltd. ., Ltd na ihe karịrị ụlọ ọrụ 100 n'ụlọ na mba ọzọ. 

• Ego ha nwetara: CNY ijeri 16

N'afọ 2017, Kelun họọrọ 155th n'etiti ụlọ ọrụ mmepụta ihe 500 kacha elu nke China, na ike ya zuru oke họọrọ n'etiti atọ kachasị elu na ụlọ ọrụ ọgwụ China. Na 2018, e nyere Kelun dị ka otu onye mmeri ngosi ụlọ ọrụ na ụlọ ọrụ mmepụta ihe site na uru ya zuru ụwa ọnụ na nnukwu injections. Na 2020, e nyere Kelun National Technology Innovation Demonstration Enterprise.

Edepụtara Sichuan Kelun Pharmaceutical Co., Ltd nke ọma na Shenzhen Stock Exchange na June 2010. Ozugbo ọ gara n'ihu ọha, Kelun malitere ozugbo iri ijeri ijeri ụlọ ọrụ achụmnta ego atụmatụ wee malite ime atụmatụ mmepe nke "mmepe atọ chụpụrụ. , ọhụrụ uto”.

10. Chongqing Zhifei Ngwaahịa ndu

Chongqing Zhifei Biological Products Co., Ltd. ("Zhifei" ma ọ bụ "Ụlọ ọrụ" maka nkenke) nwere ọnụnọ ya na ụlọ ọrụ ngwaahịa ndu na 2002. Ụlọ ọrụ ahụ nwetara ego na-arụ ọrụ nke RMB10.59 ijeri na 2019 site na nkwado nke fọrọ nke nta ka ọ bụrụ ụlọ ọrụ mmepụta ihe. Ndị ọrụ 3,000 dabere n'isi obodo edebanyere aha ya nke ijeri RMB1.6 na mkpokọta akụ nke ijeri RMB13.6.

Na Septemba 2010, e depụtara Zhifei na Shenzhen Stock Exchange (koodu ngwaahịa: 300122), na-aghọ ụlọ ọrụ ọgwụ mgbochi mbụ na-agba na nzuzo nke edepụtara na ChiNext. Zhifei nwere ụlọ ọrụ ise nwere kpamkpam yana enyemaka nkwonkwo, nke Beijing ZhifeiLvzhu Biopharmaceutical Co., Ltd. na Anhui ZhifeiLongcom Biopharmaceutical Co., Ltd bụ ụlọ ọrụ ọgbara ọhụrụ dị elu.

• Ego ha nwetara: CNY ijeri 14

Ngwaahịa ụlọ ọrụ dị na azụmaahịa gụnyere Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) (Ekear®), Haemophilus Influenzae Ụdị b Vaccine (XiFeiBei®), Group ACYW₁₃₅ Vaccine Meningococcal Polysaccharide (Menwayc®), Mycobacterium Vaccae for Injection (Vaccae®), Meningococcal Group A na Group C Polysaccharide Conjugate Vaccine (Mening A Con®), na ngwaahịa ndị ọzọ emepụtara onwe ha. Ka ọ dị ugbu a, Zhifei bụ naanị onye na-ekesa ọgwụ mgbochi nke Merck Sharp & Dohme (MSD) dị ka HPV4 (Gradasil), HPV9 (Gradasil 9), ọgwụ mgbochi rotavirus 5-valent (Rotateq), ọgwụ mgbochi oyibo 23-valent (Pneumovax 23), ịba ọcha n'anya. Ọgwụ mgbochi (Vaqta).